Business Wire

Northern Data: AI Leader Innoplexus Chooses Northern Data HPC Solutions to Accelerate Drug Discovery and Development Against COVID-19

Share

Northern Data AG ( XETRA: NB2, ISIN: DE000A0SMU87), one of the world's largest providers of high-performance computing (HPC) solutions, today announces a strategic partnership with Innoplexus AG to accelerate drug discovery and development against COVID-19 and other diseases.

Innoplexus is a leading global Artificial Intelligence (AI) based platform for drug discovery and development with over 300 employees in Europe, Asia and the US and more than 100 patent applications including 14 grants in artificial intelligence, machine learning, and blockchain technologies. Innoplexus clients include big pharma like Merck, Gilead; Contract Research Organizations such as PPD as well as innovative biotech firms like SanBio.

The COVID-19 pandemic is a stark reminder that drug development needs to be accelerated in order to serve patients in need. Responding to time pressure, pharmaceutical companies and research institutions around the world are now using high-performance computing (HPC) on a large scale to perform epidemiological and other in-silico calculations and simulations that would take months or even years on traditional platforms.

"Innoplexus leverages AI to generate insights across the entire value chain for drug discovery and development. Northern Data provides us and our clients with the necessary HPC infrastructure at an unparalleled quality, quantity and price level to enhance these capabilities, scaling up and accelerating our key programs even further", says Dr. Gunjan Bhardwaj, Founder & CEO, Innoplexus.

These insights are generated from enormous volumes of published and unpublished data. One pre-requisite is sufficient computational power - through scalable and efficient high-performance-computing (HPC) infrastructure. HPC offers many times the computing power that normal desktop PCs generate - thousands of high-performance computers processing billions of units of data in real-time. As a result, HPC can be used for tasks that would be impossible for regular computers or would take an impractically long time to complete. Demand for HPC is fast-growing, with many applications ranging from AI to scientific modelling to video rendering solutions. As a result, HPC capacities are scarce and difficult to secure.

HPC is complex and requires significant experience and expertise to run successfully, something that Northern Data has spent years developing successfully and in which it now occupies a world-leading position. For example, the hardware requires a magnitude more electrical energy and cooling than traditional computer systems. Conventional data centers consume power in the low double-digit megawatt range - by comparison, Northern Data's Texas plant will be operating at 1.0 gigawatt (1,000 megawatts) in its first phase by the end of the year and will be enlarged to 3.6 gigawatts over the next three years.

In order to offer Innoplexus and its clients preferred access to Northern Data's solutions and capacities especially in Europe, the companies have formed a strategic partnership.

"The HPC market has been in its infancy for the past few years but is currently skyrocketing across a range of diverse application areas. The demand for HPC exceeds supply many times over. We conservatively estimate that, over the next 18 to 24 months, the demand for HPC capacity will be thirty times higher than the resources we can build up in a year. And there is no player on the market building more capacity than we are", says Aroosh Thillainathan, CEO, Northern Data. "We are delighted to be able to contribute to the fight against the corona virus with Innoplexus as a partner. There is a massive need for HPC-capacity as we see a global race over who gets the tests and who gets the drugs. Since we are working on a global scale but at the same time both have our roots in Germany, it made a lot of sense to us to partner with Innoplexus."

He adds: "Additional to the partnership with Innoplexus, we are close to securing several more large clients. We are confident to fully provide the one-gigawatt capacity latest by the end of this year and are already working on the enlargement of our Texas site to 3.6 gigawatts in total."

About Innoplexus:

Innoplexus AG is a leading global AI-based platform for drug discovery and development with over 300 employees and 100+ patent applications including 14 grants in artificial intelligence, machine learning, and blockchain technologies. Innoplexus' solutions can generate real-time insights from hundreds of terabytes of structured and unstructured private and public data, thereby facilitating continuous, informed decision-making for its customer base at an unprecedented speed. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, as well as Hoboken, and San Francisco, United States.

About Northern Data:

Northern Data AG develops and builds global infrastructure solutions in the area of high-performance computing (HPC). The company offers solutions in areas such as machine learning and artificial intelligence, big data analytics, blockchain, game streaming and others. The international company emerged from the merger of the German Northern Bitcoin AG and the American Whinstone US, Inc. and is today a recognized market leader in the field of HPC solutions worldwide. Northern Data offers its HPC solutions both stationary in large, state-of-the-art data centers and in mobile, high-tech data centers based on containers, which can be set up at any location worldwide. It combines self-developed software and hardware with intelligent concepts for a sustainable energy supply. In Texas, Whinstone is currently building the largest HPC data center in the United States and the largest facility in the world specifically for HPC applications.

Language: English
Company: Northern Data AG
Thurn-und-Taxis-Platz 6
60313 Frankfurt/Main
Germany
Phone: +49 69 34 87 52 25
E-mail: info@northerndata.de
Internet: www.northerndata.de
ISIN: DE000A0SMU87
WKN: A0SMU8
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate Exchange

Contact information

Press:
Northern Data AG
Dr. Hans Joachim Dürr
Head of Corporate Communications
E-Mail: h.duerr@northerndata.de
Telefon: +49 69 348 752 89

Investor Relations:
Sven Pauly
E-Mail: ir@northerndata.de
Telefon: +49 89 125 09 03 31

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom